New Hampshire AG puts pain drug marketing under his microscope

Amid growing backlash from state and local lawmakers over opioid marketing, New Hampshire is investigating several drugmakers for potential violations. The state says pain drug companies may have intentionally exaggerated their products' benefits while downplaying serious risks. More from FiercePharma

Suggested Articles

A self-proclaimed former employee at Novartis’ Beijing office accused the Swiss drugmaker of expensing fake academic events to offer kickbacks to doctors.

Novo Nordisk just won an FDA approval that could help it stand out in the crowded—and competitive—basal insulin category.

Pfizer is training pharmacists in the U.K. to handle over-the-counter Viagra.